Preliminary studies have shown that gallium nitrate is effective treatment for cancer-related hypercalcemia, and that this effect is due to inhibition of calcium release from bone. In vivo studies in animals have also established that treatment with gallium nitrate increases the amount of calcium in bone. The dual effects of inhibiting bone resorption and increasing calcium accretion into newly-mineralized bone suggest that gallium nitrate will be useful for other diseases characterized by loss of bone mass, particularly cone metastases. First, we intend to establish that clinical treatment with gallium nitrate effectively reduces biochemical parameters of bone turnover in cancer patients with bone metastases. Second, since gallium must currently be administered by i.v. infusion, chronic administration would be considerably facilitated by development of a subcutaneous (SQ) route. We will perform a toxicologic study of the SQ route in rodents which will allow the use of this injection method in humans. Subsequently, a bioavailability and pharmacokinetic study of subcutaneously administered gallium nitrate will be conducted. Third, gallium nitrate will be administered over a 6 month period to a selected group of cancer patients who have disease primarily limited to bone. This study is intended to demonstrate that chronic treatment with gallium nitrate increases the mineral content of bone at both disease-involved and uninvolved sites. A positive result from these pilot studies will serve as a basis for a randomized study of gallium nitrate vs. placebo as adjuvant treatment for patients with bone metastasis. Documentation of this novel use for a drug which both retards bone resorption and increases calcium accretion into bone would be expected to reduce bone pain and fractures which are a major source of morbidity in cancer patients with bone metastasis.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA042445-03
Application #
3183768
Study Section
Experimental Therapeutics Subcommittee 2 (ET)
Project Start
1986-06-01
Project End
1989-05-31
Budget Start
1988-06-01
Budget End
1989-05-31
Support Year
3
Fiscal Year
1988
Total Cost
Indirect Cost
Name
Memorial Hospital for Cancer & Allied Di
Department
Type
DUNS #
City
New York
State
NY
Country
United States
Zip Code
10021
Warrell Jr, R P; Lovett, D; Dilmanian, F A et al. (1993) Low-dose gallium nitrate for prevention of osteolysis in myeloma: results of a pilot randomized study. J Clin Oncol 11:2443-50
Burtis, W J; Brady, T G; Orloff, J J et al. (1990) Immunochemical characterization of circulating parathyroid hormone-related protein in patients with humoral hypercalcemia of cancer. N Engl J Med 322:1106-12
Warrell Jr, R P; Bosco, B; Weinerman, S et al. (1990) Gallium nitrate for advanced Paget disease of bone: effectiveness and dose-response analysis. Ann Intern Med 113:847-51
Bockman, R S; Warrell Jr, R P; Levine, B et al. (1990) Trace elemental analysis in bone using x-ray microscopy. Basic Life Sci 55:293-6
Bockman, R S; Repo, M A; Warrell Jr, R P et al. (1990) Distribution of trace levels of therapeutic gallium in bone as mapped by synchrotron x-ray microscopy. Proc Natl Acad Sci U S A 87:4149-53
Warrell Jr, R P; Bockman, R S (1989) Gallium in the treatment of hypercalcemia and bone metastasis. Important Adv Oncol :205-20
Warrell Jr, R P; Muindi, J; Stevens, Y W et al. (1989) Induction of profound hypouricemia by a non-sedating thiobarbiturate. Metabolism 38:550-4
Warrell Jr, R P; Israel, R; Frisone, M et al. (1988) Gallium nitrate for acute treatment of cancer-related hypercalcemia. A randomized, double-blind comparison to calcitonin. Ann Intern Med 108:669-74
Warrell Jr, R P; Issacs, M; Alcock, N W et al. (1987) Gallium nitrate for treatment of refractory hypercalcemia from parathyroid carcinoma. Ann Intern Med 107:683-6
Warrell Jr, R P; Alcock, N W; Bockman, R S (1987) Gallium nitrate inhibits accelerated bone turnover in patients with bone metastases. J Clin Oncol 5:292-8